Annual EBITDA
-$163.75 M
-$33.36 M-25.58%
December 31, 2023
Summary
- As of February 7, 2025, AVIR annual EBITDA is -$163.75 million, with the most recent change of -$33.36 million (-25.58%) on December 31, 2023.
- During the last 3 years, AVIR annual EBITDA has fallen by -$152.74 million (-1387.11%).
- AVIR annual EBITDA is now -218.31% below its all-time high of $138.41 million, reached on December 31, 2021.
Performance
AVIR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$37.10 M
+$9.71 M+20.75%
September 30, 2024
Summary
- As of February 7, 2025, AVIR quarterly EBITDA is -$37.10 million, with the most recent change of +$9.71 million (+20.75%) on September 30, 2024.
- Over the past year, AVIR quarterly EBITDA has increased by +$3.58 million (+8.81%).
- AVIR quarterly EBITDA is now -130.61% below its all-time high of $121.19 million, reached on December 31, 2021.
Performance
AVIR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$200.08 M
+$3.58 M+1.76%
September 30, 2024
Summary
- As of February 7, 2025, AVIR TTM EBITDA is -$200.08 million, with the most recent change of +$3.58 million (+1.76%) on September 30, 2024.
- Over the past year, AVIR TTM EBITDA has dropped by -$43.01 million (-27.38%).
- AVIR TTM EBITDA is now -244.56% below its all-time high of $138.41 million, reached on December 31, 2021.
Performance
AVIR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AVIR EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -25.6% | +8.8% | -27.4% |
| 3 y3 years | -1387.1% | +8.8% | -27.4% |
| 5 y5 years | -1630.9% | +8.8% | -27.4% |
AVIR EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -218.3% | at low | -130.6% | +46.8% | -244.6% | +1.8% |
| 5 y | 5-year | -218.3% | at low | -130.6% | +46.8% | -244.6% | +1.8% |
| alltime | all time | -218.3% | at low | -130.6% | +46.8% | -244.6% | +1.8% |
Atea Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$37.10 M(-20.8%) | -$200.08 M(-1.8%) |
| Jun 2024 | - | -$46.81 M(-32.8%) | -$203.66 M(+6.1%) |
| Mar 2024 | - | -$69.70 M(+50.0%) | -$191.98 M(+17.2%) |
| Dec 2023 | -$163.75 M(+25.6%) | -$46.47 M(+14.2%) | -$163.75 M(+4.2%) |
| Sep 2023 | - | -$40.68 M(+15.8%) | -$157.07 M(+18.5%) |
| Jun 2023 | - | -$35.13 M(-15.3%) | -$132.57 M(+2.2%) |
| Mar 2023 | - | -$41.47 M(+4.2%) | -$129.69 M(-0.5%) |
| Dec 2022 | -$130.39 M(-194.2%) | -$39.80 M(+146.0%) | -$130.39 M(-526.2%) |
| Sep 2022 | - | -$16.18 M(-49.8%) | $30.59 M(+24.2%) |
| Jun 2022 | - | -$32.25 M(-23.5%) | $24.63 M(-62.4%) |
| Mar 2022 | - | -$42.17 M(-134.8%) | $65.58 M(-52.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | $138.41 M(-1357.0%) | $121.19 M(-647.4%) | $138.41 M(+265.5%) |
| Sep 2021 | - | -$22.14 M(-354.6%) | $37.87 M(-10.7%) |
| Jun 2021 | - | $8.70 M(-71.6%) | $42.39 M(+78.9%) |
| Mar 2021 | - | $30.66 M(+48.5%) | $23.69 M(-315.2%) |
| Dec 2020 | -$11.01 M(-24.5%) | $20.65 M(-217.2%) | -$11.01 M(-69.8%) |
| Sep 2020 | - | -$17.62 M(+76.3%) | -$36.41 M(+61.5%) |
| Jun 2020 | - | -$10.00 M(+147.4%) | -$22.55 M(+79.7%) |
| Mar 2020 | - | -$4.04 M(-14.8%) | -$12.55 M(+47.5%) |
| Dec 2019 | -$14.59 M(+54.2%) | -$4.75 M(+26.0%) | -$8.51 M(+126.0%) |
| Sep 2019 | - | -$3.77 M | -$3.77 M |
| Dec 2018 | -$9.46 M | - | - |
FAQ
- What is Atea Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Atea Pharmaceuticals?
- What is Atea Pharmaceuticals annual EBITDA year-on-year change?
- What is Atea Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Atea Pharmaceuticals?
- What is Atea Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Atea Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Atea Pharmaceuticals?
- What is Atea Pharmaceuticals TTM EBITDA year-on-year change?
What is Atea Pharmaceuticals annual EBITDA?
The current annual EBITDA of AVIR is -$163.75 M
What is the all time high annual EBITDA for Atea Pharmaceuticals?
Atea Pharmaceuticals all-time high annual EBITDA is $138.41 M
What is Atea Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, AVIR annual EBITDA has changed by -$33.36 M (-25.58%)
What is Atea Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of AVIR is -$37.10 M
What is the all time high quarterly EBITDA for Atea Pharmaceuticals?
Atea Pharmaceuticals all-time high quarterly EBITDA is $121.19 M
What is Atea Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, AVIR quarterly EBITDA has changed by +$3.58 M (+8.81%)
What is Atea Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of AVIR is -$200.08 M
What is the all time high TTM EBITDA for Atea Pharmaceuticals?
Atea Pharmaceuticals all-time high TTM EBITDA is $138.41 M
What is Atea Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, AVIR TTM EBITDA has changed by -$43.01 M (-27.38%)